People of all ages with asthma can halve the number of asthma attacks they suffer and become 15% better at taking their medication if they use a medical-grade App to manage their health¹.
Smart Inhalers are great, but they have one big problem: they need to be connected to your smartphone to send their data. This can be a problem for younger children at school who aren’t allowed to have a Smartphone—or older patients with asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis or other lung health problems who find using a smartphone difficult.
Aseptika, a UK company that specialises in making smart inhalers for patients with long-term respiratory conditions, has been co-funded by the UK’s Innovation Agency, Innovate UK. The Smart Award will help the company develop its third-generation smart inhaler tracker, which will have 5G mobile connectivity built-in. This means that patients will no longer have to send their data via a smartphone to their clinical teams, carers or parents—it will just send information over the airwaves directly to the Company’s cloud databases, which are stored under the UK's data protection laws
The new PUFFClicker3 will not only be a universal device for both the cylinder-type inhalers that young children and older patients use (Metered Dose Inhalers), but also the dry powder inhalers which many adults are now prescribed because they do not have gasses which contribute to global heating.
This new inhaler tracker will also be “smart” and will give information and advice to patients on how to take their medicines properly. Its software will run on Aseptika’s Medi-OS medical-grade operating system so that it can be approved as a medical device in the UK (UKCA mark) as well as in other countries around the world (CE mark as a Class IIa medical device under EU MDR 2017/745).
Another benefit of transmitting data without a Smartphone is that it makes it easier to export because the multilanguage PUFFClicker3 can work with locally developed Apps without having to connect to it by Bluetooth. This makes integration quicker, cheaper and means that these Apps may not have to be certified a Class IIa medical device to display the information that the PUFFClicker3 collects.
The Company expects to take PUFFClicker3 into production by the end of 2023 and launch it in the UK and internationally in early 2024.
–Ends–
References
1. Chan A, De Simoni A, Wileman V, Holliday L, Chisari C, Newby CJ, Griffiths CJ, Ali S, Padakanti P, Zhu N, Ting V, Pinprachanan V, ‘Digital interventions to improve adherence to maintenance medication in asthma’. Cochrane Database of Systematic Reviews. DOI: https://doi.org/10.1002/14651858.CD013030.pub2
Picture showing how the PUFFClicker3 will connect to a range of dry powder inhalers.
Further information
Activ8rlives, Activ8rlives.com, Asthma⁺me, Active⁺me REMOTE and PUFFClicker are trademarks of Aseptika Ltd.
For further details, please contact Jessica Auton on +44 (0)1480 352 821 or email jessica.auton@aseptika.com
For a case study of PUFFClicker use with children and young people follow this link.
Innovate UK Logo.
Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas.
We connect businesses to partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth.
We fund business and research collaborations to accelerate innovation and drive business investment into R&D.
Innovate UK is part of UK Research and Innovation.
For more information visit www.innovateuk.ukri.org
Aseptika Ltd www.activ8rlives.com
Aseptika Ltd began developing Activ8rlives in 2010 and is currently developing its fourth generation of integrated systems, which can be used by consumers and their healthcare service providers using a wide range of platforms or devices to better enable effective and easy remote self-monitoring. Incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs). Our focus is: respiratory and cardiovascular disease, cancer, promoting physical activity and weight management. Aseptika Limited has been certified by BSI to ISO 13485:2016 under certificate number MD691414.